TLR4 and breast carcinoma: It also activates the TLR4/MyD88 pathway in breast cancer, leading to the upregulation of NF-κB pathway-associated cytokines such as IL-1β or TNF-α, exerting direct or indirect immunosuppressive effects [76,77].